Puromycin-sensitive aminopeptidase inhibitors for effective pain management
Novel puromycin-sensitive aminopeptidase (PSA) inhibitors with analgesic properties.
Applications
- Pain management
Key Benefits & Differentiators
- Avoids opioid use: These compounds provide a non-opioid alternative for pain management
- Increased efficacy: Other non-opioid agents provide insufficient pain relief, limiting their applications
- Reduced toxicity: Unlike previously studied PSA inhibitors, these compounds do not metabolize to toxic byproducts
Technology Overview
Chronic pain affects millions of individuals worldwide, leading to a substantial impact on quality of life and significant healthcare costs. Traditional opioid medications, while effective at managing pain, come with severe side effects, including the risk of addiction and overdose. Attempts have been made to address these problems with non-opioid agents such as non-steroidal anti-inflammatory agents and local anesthetics, however insufficient pain relief greatly limits their clinical impact. As a result, there is a critical need for safer and more effective pain management strategies.
Researchers at the University of Minnesota have developed novel puromycin-sensitive aminopeptidase (PSA) inhibitors that have analgesic properties. By targeting the inhibition of PSA, enkephalin degradation is reduced, leading to increased levels of endogenous opioid peptides in the body, which offers increased pain relief and a promising alternative to traditional opioid therapies. This solution avoids opioid receptor overstimulation, thus dependence and addiction are avoided.
Phase of Development
TRL: 3-4In vitro and in vivo data has been collected on the efficacy, stability, and toxicity of these compounds.
Desired Partnerships
This technology is now available for:- License
- Sponsored research
- Co-development
Please contact our office to share your business’ needs and learn more.
Researchers
- Robert Vince, PhD Professor and Director, Center for Drug Design
- Swati S. More, PhD Professor, Center for Drug Design
-
swap_vertical_circlelibrary_booksReferences (1)
- Rohit Singh, Rongrong Jiang, Jessica Williams, Prakashkumar Dobariya, Filip Hanak, Jiashu Xie, Patrick E. Rothwell, Robert Vince, Swati S. More (2024), Modulation of endogenous opioid signaling by inhibitors of puromycin-sensitive aminopeptidase, European Journal of Medicinal Chemistry
-
swap_vertical_circlecloud_downloadSupporting documents (1)Product brochurePuromycin-sensitive aminopeptidase inhibitors for effective pain management.pdf